Ogechukwu Egini

RH Provider

Egini%202023%20PREFERRED.jpg

Ogechukwu Egini, MD, MS

Specialties:
bone marrow/stem cell transplantation bone marrow failure disorder cancer genetics CAR T-cell therapy clinical trials hematologic malignancies leukemia lymphoma medical oncology myeloma sickle cell disease  

Academic Appointments:
  • Hematologist/Oncologist
  • Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Aetna US HealthCare
Aetna, Inc.
Amerigroup
AmeriHealth HMO
Champ VA
Cigna
Cigna Healthcare
Emblem Health
GHI
Health Republic
HealthFirst
Horizon
Horizon BCBS Managed Care
Horizon NJ Health, Inc.
Magnacare
Medicaid
Medicare
MultiPlan
Oxford Health Plans
Private Healthcare Systems
Qualcare HMO
Qualcare PPO
Tricare
United Healthcare
United Healthcare Community Plan
Provider Biography

My philosophy of care is undergirded by compassion, honesty, transparency and shared decision-making with the patient. I believe our patients choose us -- we do not choose them. So each time I meet a new patient, I make an attempt to know them and understand what is important to them so that we can work together to best care for them and craft a personalized, comprehensive and compassionate care plan.

Board-certified in internal medicine, hematology and oncology, I am trained to take care of patients who have a variety of cancerous and non-cancerous blood disorders -- specifically those needing blood and marrow transplantation and cellular therapies including CAR T-cell therapy.

I attended medical school at Nnamdi Azikiwe University in Nigeria graduating on the Dean's Honors list. I then completed Internal Medicine Residency training at Interfaith Medical Center followed by Hematology/Oncology training at SUNY Downstate Health Sciences University, both in Brooklyn, NY. I completed training in Blood and Marrow Transplantation and Cellular Therapy at Stanford University, Stanford, CA.

My research interests are in improving allo-transplantation outcomes, minimizing graft-versus-host-disease (GVHD), improving selection of CAR T patients, global health and improving health care disparities. I am always looking for new ways to collaborate with my colleagues to apply the best scientific evidence in a compassionate manner to care for our patients.